OAK BROOK, Ill.--(BUSINESS WIRE)--Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged in the commercial development of vaccines for the prevention and treatment of human infectious diseases, announced today that it has executed a non-binding letter of intent to acquire 51% of Lanzhou Roya Biotechnology Co. Ltd., based in the People’s Republic of China. Lanzhou Roya is a bovine serum manufacturer in China. The serum market size in China is estimated to be RMB 500 million per annum. Bovine serum is used in production of many vaccines as well as for laboratory scientific research.
